This content is machine translated Type 2 diabetes ESC recommendations for reducing cardiovascular risk Patients with type 2 diabetes have a greatly increased risk of developing cardiovascular disease compared to healthy people in the same age group. The current guidelines published in the European…
View Post 5 min This content is machine translated Chronic renal failure New therapy standard on the rise Several innovative therapeutic options are expanding the options for treating patients with chronic kidney disease ( CKD). SGLT-2 inhibitors (SGLT-2-i) can now be considered an established treatment option – even…
View Post 5 min This content is machine translated Heart failure in type 2 diabetes Success story of SGLT-2 inhibitors – impressive evidence base. The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
